- Diagnostic Différentiel
Drug Information for MOXATAG™ (amoxicillin extended-release) Tablets (MiddleBrook Pharmaceuticals, Inc.): CLINICAL STUDIES
- DOSAGE FORMS AND STRENGTHS
- ADVERSE REACTIONS
- CLINICAL STUDIES
- HOW SUPPLIED, STORAGE AND HANDLING
- Liens externes liés à MOXATAG™ (amoxicillin extended-release) Tablets (MiddleBrook Pharmaceuticals, Inc.)
In a randomized, parallel-group, multi-center, double-blind, double-dummy study in adults and pediatrics (age≥ 12 years) with tonsillitis and/or pharyngitis secondary to S. pyogenes, MOXATAG 775 mg QD for 10 days was non-inferior to penicillin VK 250 mg QID for 10 days.
Using strict evaluability and microbiologic response criteria 4-8 days post-therapy, the following bacteriological eradication rates and statistical outcomes in the per-protocol (PPb) and modified intent-to-treat (mITT) populations were obtained (Table 4). The mITT population included all randomized patients with a positive throat culture for S. pyogenes at baseline. The PPb population included mITT patients who had post-therapy cultures, were compliant with treatment, and didn't have major protocol violations.
Table 4. Bacteriological Eradication Rates in Patients with Tonsillitis and/or Pharyngitis StudyPopulation MOXATAG Penicillin VK Rate Difference95% CI (%) PPb 198/233(85.0%) 191/229(83.4%) 1.6 (-5.1, 8.2) mITT 204/256(79.7%) 206/264(78.0%) 1.7 (-5.4, 8.7)
- Drug Information Provided by National Library of Medicine (NLM).